Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG2403 B-CHECK-AD adjuvant therapy in resected BRAF V600-mutant melanoma
jRCT1031250352Phase 3Recruiting
- Sponsor
- Japan Clinical Oncology Group
- Start
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in cutaneous melanoma (CM) comparing Adjuvant anti-PD-1 antibody with Adjuvant dabrafenib + trametinib (2 arms). Primary endpoint: Relapse-free survival. Started Oct 2025; status: recruiting.
02
Drugs
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on jRCT1031250352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250352.